bleselumab

DRUG2 trials

Sponsors

Astellas Pharma Inc, Astellas Pharma Global Development, Inc.

Conditions

Kidney TransplantationPrimary Focal Segmental Glomerulosclerosis (FSGS)

Phase 1

A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation

CompletedNCT01279538

Astellas Pharma IncKidney Transplantation

Start: 2010-11-17End: 2012-01-23Updated: 2025-11-17

Phase 2

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

CompletedNCT02921789

Astellas Pharma Global Development, Inc.Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)

Start: 2017-05-22End: 2021-05-18Updated: 2024-12-04

Related Papers

A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.

2019-09-0927 citations